An exploratory study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

The company Shanghai Pulmonary Hospital, Shanghai, China is commencing recruitment for the clinical trial of the A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB.

The trial officially began on the August 3, 2022 and is planned to complete on August 3, 2027.

A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.

The population that can be enrolled into this study includes:

• RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin). - Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs. Exclusion Criteria: - Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc. - Test confirms poor response to ZOL and IL-2 stimulation.

Patients with the following pathologies:

• Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc. - Test confirms poor response to ZOL and IL-2 stimulation.

are excluded from participation.

Shanghai Public Health Clinical Center, Huashan Hospital, No.85 Hospital, Changning, Shanghai, China are the collaborators in this clinical trial.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05493267.